The massive success of cell and gene therapies in recent years has made the need for effective, large scale vector engineering greater than ever. Though R&D efforts focussed on reducing immunogenicity and toxicity whilst improving redosing ability and durability are showing promise, companies are still striving to optimise these technologies and develop next-generation targeted, persistent and tolerable cell and gene therapies.
WHY ATTEND
The Vector Development for Cell and Gene Therapy Summit is North America’s only event focused exclusively on addressing challenges in vector improvement for both ex vivo and in vivo approaches. Bringing together key industry leaders and covering a range of topics including capsid optimisation using AAV vectors, process optimisation using lentiviral and adenoviral vectors, innovative non-viral delivery options and the importance of vector serotype for improved durability, it’s a key opportunity to gain the actionable insights you’ll need to optimise your manufacturing process and improve tissue-specific targeting and safety profiles for your pipeline.
BENEFITS
|
BUILD A CLEAR STRATEGY |
STREAMLINE YOUR VECTOR PROCESS DEVELOPMENT AND MANUFACTURING |
|
IMPROVE THE SAFETY AND EFFICACY AND REDUCE IMMUNOGENICITY |
ENHANCE YOUR DISCOVERY AND DEVELOPMENT PROCESSES |
WHO WILL BE THERE
- Senior-level leaders from biotech and big pharma
- Internationally-renowned academic experts
- Innovative vector development technology companies
- Service & technology providers – CROs, CDMOs, delivery technology companies and more
WHAT TO EXPECT
- Two dedicated tracks focused on in vivo and ex vivo vector optimization (REGENXBIO, Spark Therapeutics, Umoja Biopharma), developing more efficient producer cell lines (talks from Vedere Bio, Ultragenyx, Sanofi) and process development improvements (talks from Pfizer, LogicBio, Bristol Myers Squibb).
- Specific talks and discussion on how to efficiently meet the requirements in bringing drugs to market (Sangamo Therapeutics, Ring Therapeutics).
- Exploration of the most effective vector serotypes to produce more durable gene expression (talks from SparingVision, MIT, Codiak Biosciences, Versatope Therapeutics).
- Discussing the cutting-edge methods to reduce timelines for cell and gene therapy drug development (talks from University of Pennsylvania, Biogen).
- Developing novel vectors to reduce immunogenicity, allowing for effective redosing (talks from SmartImmune, Genethon, UC Berkeley).
Event Venue: Boston
Event Website: https://hubs.ly/Q01dbNrB0
Event Organizer: Kisaco Research
Contact No: +44 (0)20 3696 2920
Email ID: events@kisacoresearch.com
Hilton Boston Back Bay , Boston, MA, USA